Please ensure Javascript is enabled for purposes of website accessibility

Why Teladoc Health Flew 9% Higher on Friday

By Eric Volkman - May 13, 2022 at 7:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst bucks the trend and lifts her price target on the stock.

What happened

To butcher an old saying, a rising tide lifts most boats. A surging stock market helped push shares of Teladoc Health (TDOC 0.47%) higher by more than 9% on Friday. But bullish investor sentiment wasn't the only reason for that gain; an analyst's price-target increase also helped.

So what

That increase was hardly dramatic, but it drew attention to Teladoc and helped bring investors back to the stock. The raiser was Piper Sandler prognosticator Jessica Tassan, who now thinks the shares are worth $42, a bump from her previous estimation of $41. She is maintaining her overweight (buy) recommendation on the stock.

Two people engaging in a discussion through a laptop video communications app.

Image source: Getty Images.

According to analyst-recommendation tracking website, Tassan made the adjustment on the basis of conversations with Teladoc officials and an analysis of the direct-to-consumer healthcare market, among other factors.

This resulted in the tweaking of estimates for the company's BetterHelp and Chronic Condition businesses.

Now what

Could this be the start of a bull run for Teladoc stock? After all, it's generally been beaten down over the past year, to the point where it hit all-time lows recently. Many investors see it as a pandemic stock with weaker potential now that the coronavirus threat seems as if it might be receding. A massive $6.6 billion goodwill charge in its most recently reported quarter and reduced 2022 guidance for crucial line items like revenue and net loss didn't help matters.

What also hurts is that, Tassan's price-target bump aside, many Teladoc analysts have grown more sour on the stock. Wells Fargo and Citigroup, to name two, both downgraded their recommendations on the shares to the equivalent of neutral while dramatically cutting their price targets.

It's too soon to tell whether this is the beginning of a rally in the shares, but it's clear that there are plenty of bulls behind the stock. Perhaps they'll at least support its price as we (hopefully) emerge from the pandemic.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$31.88 (0.47%) $0.15
Piper Sandler Companies Stock Quote
Piper Sandler Companies
$129.04 (2.75%) $3.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.